This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Karlowsky, J. A.
Right arrow Articles by Zhanel, G. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karlowsky, J. A.
Right arrow Articles by Zhanel, G. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2009, p. 3544-3548, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00400-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity{triangledown}

James A. Karlowsky,1* Nachum Kaplan,2 Barry Hafkin,2 Daryl J. Hoban,1 and George G. Zhanel1

Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada,1 Affinium Pharmaceuticals, Inc., Toronto, Ontario, Canada2

Received 25 March 2009/ Returned for modification 9 May 2009/ Accepted 23 May 2009

AFN-1252, a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of Staphylococcus aureus (n = 502) and Staphylococcus epidermidis (n = 51) tested, including methicillin (meticillin)-resistant isolates, at concentrations of ≤0.12 µg/ml. In contrast, AFN-1252 was inactive (MIC90, >4 µg/ml) against clinical isolates of Streptococcus pneumoniae, beta-hemolytic streptococci, Enterococcus spp., Enterobacteriaceae, nonfermentative gram-negative bacilli, and Moraxella catarrhalis. These data support the continued development of AFN-1252 for the treatment of patients with resistant staphylococcal infections.

* Corresponding author. Mailing address: Department of Clinical Microbiology, Health Sciences Centre, MS673C, 820 Sherbrook St., Winnipeg, Manitoba R3A 1R9, Canada. Phone: (204) 787-4597. Fax: (204) 787-4699. E-mail: jkarlowsky{at}hsc.mb.ca

{triangledown} Published ahead of print on 1 June 2009.

Antimicrobial Agents and Chemotherapy, August 2009, p. 3544-3548, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00400-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»